GlassScriptPhysician profile
Larry A Henderson
NPI 1215976022
$1,172.06
in general payments reported to CMS, 2019-2025
21 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $243 · 2021: $83.67 · 2022: $14.46 · 2023: $121 · 2024: $193 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.59 | 2019-2025 | Xifaxan |
| Pfizer INC. | $198.89 | 2019-2024 | |
| Novo Nordisk INC | $176.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $93.04 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $50.97 | 2019 | |
| Abbvie INC. | $47.69 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $45.14 | 2019-2020 | |
| Amgen INC. | $33.54 | 2024-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $31.23 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $25.45 | 2019-2020 | |
| Allergan, INC. | $22.60 | 2019-2020 | |
| Axsome Therapeutics, INC. | $18.51 | 2025 | Sunosi |
| Ibsa Pharma INC. | $17.46 | 2024 | Tirosint, Licart |
| Paratek Pharmaceuticals, INC. | $17.38 | 2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $14.98 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12.74 | 2023 | Mounjaro |
| Boston Scientific Corporation | $12.74 | 2019 | |
| Astellas Pharma US INC | $12.11 | 2019 | |
| Genentech USA, INC. | $12.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.98 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.